Itch-Focused Creabilis Finally Secures Its Future Through US Sale

Creabilis has finally secured the future of its Phase III-ready psoriatic itch candidate CT327 – through a sale of the company to young US firm Sienna Biopharmaceuticals.

Psoriasis

Sienna Biopharmaceuticals Inc. of California, a privately held medical dermatology and aesthetics company, has acquired Creabilis SA (more recently a PLC), for an undisclosed upfront payment in cash and stock, as well as additional payments dependent on achieving specific regulatory and commercial milestones, which could exceed $150m.

Creabilis has been ready to start Phase III trials for quite some time: initial Phase IIb data were reported in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip